NCT06767267 (PAM_2022) is a clinical trial in Otomastoiditis, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT06767267?

NCT06767267 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What condition does NCT06767267 study?

NCT06767267 studies Otomastoiditis.

Is NCT06767267 still recruiting?

NCT06767267 is currently recruiting now. Last updated 9 January 2025.

Last reviewed 2025-01-09 · How we verify

NCT06767267: PAM_2022

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiology of Acute Otomastoiditis in Pediatric Age

Recruiting now Last updated 9 January 2025

What this trial tests

trial in Otomastoiditis in 350 participants. Currently enrolling.

Timeline

13 March 2024

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	350
Start date	13 March 2024
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Italy

Conditions studied

Otomastoiditis — all drugs for Otomastoiditis →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Under 14, any sex, with Otomastoiditis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It was decided to conduct this study because there are no standardized guidelines. regarding the management of acute otomastoiditis. The aim of the study is to describe the epidemiology of otomastoiditis in order to outline the scientific and rational basis necessary to standardize the diagnostic and therapeutic approach to this condition in order to reduce the diagnostic delay and improve the therapeutic outcome. It also aims to evaluate the effectiveness of different treatment modalities and identify possible risk factors associated with complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06767267 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 9 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06767267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing